|
www.aurobindo.com |
|
|
|
|
Aurobindo Pharma purchases US
FDA - Compliant facility in Dayton, NJ |
|
|
|
Aurobindo pharma Ltd
is pleased to announce that it has acquired a US
FDA compliant cGMP facility in Dayton, New
Jersey for US$ 19 Million. |
|
The facility is
spread over 20 acres of free hold land and is
located in the heart of Princeton Life Sciences
Corridor in the state of New Jersey. The campus
is comprised of 100,000 square feet of fully
integrated state of the art R&D, formulation
manufacturing and distribution facilities with
potential for future expansion. This facility
will serve as Aurobindo’s US head quarters. |
|
Mr. Ramaprasad Reddy,
Chairman, Aurobindo Pharma, said that this
purchase reinforces Aurobindo’s commitment to
serve US market in an effective manner. |
|
Aurobindo had recently
concluded zero percent, foreign currency
convertible bonds issue of US $ 200 million.
Part of the proceeds will be used for the
purchase. |
|
About Aurobindo Pharma Limited: |
|
Aurobindo
Pharma Limited (www.aurobindo.com),
headquartered at Hyderabad, India, manufactures
generic pharmaceuticals and active
pharmaceutical ingredients. The company’s robust
product portfolio is spread over 6 major
therapeutic/product areas encompassing
(Antibiotics, Anti-Retrovirals, CVS/Statins/Diabetology,
CNS, Gastro/Uro/Kidney therapeutics, Anti
fungal/allergics/respiratory) around 65
Betalactam APIs and 123 Non-Betalactam APIs. |
|
The Company markets
its products in over 100 countries. The company
has filed over 50 ANDAs and 69 DMFs for the USA
market, in addition to several filings in other
countries. The company has received approvals
for several facilities from leading regulatory
agencies like US FDA, UK MHRA, WHO, Health
Canada, MCC South Africa. |
|
For further information,
please contact:
Investor Relations
Aurobindo Pharma Limited
Plot # 2, Maitri Vihar | Ameerpet
Hyderabad - 500 038 |India
Phone (Board): +91 40 5572 5000
Email : ir@aurobindo.com |
|
Unit
Certifications |
|
Unit |
Certifications |
|
API |
|
Unit I |
US FDA |
|
Unit 1 A |
US FDA |
|
Unit VI A |
Health Canada, US FDA
(pre approval over) |
|
Unit VIII |
US FDA, WHO |
|
Unit XI |
US FDA |
|
Formulations |
|
Unit III |
US FDA, UK MHRA,
WHO, Health Canada, MCC (SA), Brazil Anvisa
|
|
Unit VI B |
US FDA, MCC (SA), Health
Canada, Brazil Anvisa |
|
Unit XII |
US FDA, Health
Canada, UK MHRA, Brazil Anvisa
|
|
|
|
|
|
|
|
|
PRESS
ROOM
